Intra-Cellular Therapies Appoints Dr. Suresh Durgam as

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
51
Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs

NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the expansion of the senior leadership team with the appointment of Suresh Durgam M.D as Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Durgam, brings over 15 years of experience in neuropsychiatric drug development, including the development of antipsychotics and antidepressants.

Dr. Durgam most recently served in clinical development leadership roles at Allergan plc where he was the clinical lead responsible for development of treatments for mood disorders including rapid-acting antidepressant programs.  Dr. Durgam was also the clinical development lead of the antipsychotic, cariprazine, advancing the compound from Phase I to approval in schizophrenia and bipolar disorder.

Dr. Durgam graduated with his medical degree from the Siddhartha Medical College in India and received his residency training in psychiatry at Scott & White Clinic and Hospital – Texas A&M University System College of Medicine.

“We are very pleased to welcome Dr. Durgam to Intra-Cellular as he brings additional expertise to our clinical programs.  We believe his contributions will be invaluable as we continue to advance lumateperone and our pipeline,” said Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies.

“I am excited to join Intra-Cellular Therapies. Lumateperone has a novel mechanism of action with the potential to address unmet medical needs in schizophrenia and other neuropsychiatric disorders including bipolar disorder, agitation associated with dementia, and depression,” stated Dr. Durgam. “I look forward to contributing to the success of these programs and further broadening our scope into additional therapeutic areas.”

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and for the treatment of heart failure.

Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone: 646-440-9333

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cannabis Industry Pushes for Robust Financial Services

Updated Category News Views 3

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Continue Reading
Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Updated Category News Views 3

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 1

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

Updated Category News Views 2

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Continue Reading
WNET's 25th Anniversary 9/11 Tribute: Stories and Lessons

Updated Category News Views 3

Reflecting on a Dark Day with WNET's Programming Nothing quite hits you like the anniversary of a colossal tragedy. The memories of September 11, 2001, remain etched in the urban landscape of New York City, and this year marks 25 years since that heart-wrenching day. The WNET Group steps up to the plate with a comprehensive slate of programming aimed at honoring the...

Continue Reading
Shareholder Rights in Focus: Examining Key Buyouts

Updated Category News Views 4

Shareholder Concerns Rise Amid Corporate Buyouts The stakes are high for the shareholders of Distribution Solutions Group, Eagle Financial Services, Safety Insurance Group, and Utz Brands as their companies face potential buyouts. Let's chew over what's on the table: the sweet deals insiders might score and the legal maneuvers in play. Halper Sadeh LLC, a heavy-hitting...

Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies

Updated Category News Views 1

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Continue Reading
Diaper Affordability: A Hidden Crisis, Taxpayer Burden

Updated Category News Views 4

A Silent Crisis Lurking in Diapers Diapers. We don’t think about them much until we need them, but nearly half of U.S. families are painfully aware of their cost. According to a report from the NDBN Diaper Check 2026, many struggle to meet this basic necessity. This isn't just about keeping babies clean—it's a public health issue with economic ripples Congress can't...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 1

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 1

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Liver Biopsy Market to Surge with Innovative Techniques

Updated Category News Views 175

Understanding the Growth of the Liver Biopsy Market The liver biopsy market demonstrates robust growth, projected to reach USD 1.65 billion. A recent report highlights that in 2023, the market valuation stood at approximately USD 0.90 billion. This significant increase is primarily attributed to the rising incidences of liver diseases and advancements in biopsy...

Continue Reading
CarParts.com to Showcase Innovations at Key Investment Event

Updated Category News Views 123

CarParts.com to Showcase Innovations at Key Investment Event CarParts.com, Inc. (NASDAQ: PRTS), a leading e-commerce provider of automotive parts and accessories, is excited to announce its presence at the 19th annual LD Micro Main Event. This highly anticipated event will be held at the picturesque Hotel del Coronado in San Diego. Ryan Lockwood, the Chief Financial...

Continue Reading
Sabina Adamski Introduces Her New Lending Team at Guaranteed Rate Affinity

Updated Category News Views 138

The Launch of The Sabina Adamski Group In a transformative move within the mortgage sector, Sabina Adamski has officially launched The Sabina Adamski Group following her return to Guaranteed Rate Affinity as Vice President of Mortgage Lending. This new initiative aims to provide a modern, client-first approach tailored for homebuyers. Expanding Reach and Enhancing...

Continue Reading
Innovative Sepsis Treatment STC3141 Hits Clinical Milestone

Updated Category News Views 308

Breakthrough Achievement for Grand Pharma's STC3141 Grand Pharmaceutical Group Limited has proudly announced a significant milestone in medical research with its innovative drug, STC3141, successfully reaching the clinical endpoint in a Phase II clinical study aimed at treating sepsis. This impressive achievement highlights not only the Group's commitment to pioneering...

Continue Reading
Vera Bradley's Fiscal Q2 Results Highlight Future Growth Plans

Updated Category News Views 176

Overview of Vera Bradley's Recent Financial Performance Vera Bradley, Inc. (Nasdaq: VRA) has shared its financial results for the second quarter of the fiscal year 2025, showing a consolidated net revenue of $110.8 million. While this marks a drop from $128.2 million from the same time last year, the company remains hopeful about its future direction. Key Financial...

Continue Reading